[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Shenyang Northern Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":273},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,10,0,[8,43,71,93,126,150,177,205,227,247],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100620849","phase-4-precision-colchicine-intervention-to-suppress-atherosclerosis-in-tet2-clonal-hematopoiesis-100620849",false,"NCT07362966","Precision Colchicine Intervention to Suppress Atherosclerosis in TET2 Clonal Hematopoiesis","Precision Colchicine Intervention to Suppress Atherosclerosis in TET2 Clonal Hematopoiesis : a Pilot Clinical Trial (PRECISE)","Inclusion Criteria:\n\n1. Age 40-85 years;\n2. Patients with recent hospitalization for documented ACS (the index event occurring 30-90 days before randomization) and meeting all of the following:\n\n   1. During the index hospitalization, patients underwent either PCI or diagnostic coronary angiography alone,\n   2. At least one non-culprit coronary lesion with 30%-70% diameter stenosis by visual estimation on coronary angiography,\n   3. Clinically stable throughout the screening period,\n   4. Receiving standard of care therapy for ACS in accordance with national guidelines,\n   5. Peripheral blood DNA available for targeted sequencing, with results demonstrating either TET2-CHIP or no CHIP-associated variants;\n3. Written informed consent.\n\nExclusion Criteria:\n\n1. Prior coronary artery bypass grafting (CABG) before documented ACS;\n2. Other clinically significant cardiovascular diseases, including moderate-to-severe valvular heart disease (moderate or severe), heart failure (NYHA class III-IV), or atrial fibrillation;\n3. Non-culprit coronary anatomy (e.g., marked tortuosity, bifurcation lesions, or small vessels \\\u003C1.5 mm in diameter) deemed to preclude plaque assessment by CCTA;\n4. Planned PCI or CABG;\n5. Abnormal liver function (ALT \\>3 times the upper limit of normal range) at randomization;\n6. Abnormal renal function (serum creatinine \\>1.5 times the upper limit of normal range or estimated eGFR \\\u003C45 mL\u002Fmin\u002F1.73 m²) at randomization;\n7. Hematologic abnormalities: anemia (hemoglobin \\\u003C100g\u002FL), thrombocytopenia (platelet count \\\u003C100×109\u002FL) or leukopenia (white blood cell \\\u003C3×109\u002FL) at randomization;\n8. Inflammatory bowel disease (Crohn's or ulcerative colitis) or active diarrhea;\n9. Symptomatic peripheral neuropathy, pre-existing progressive neuromuscular disease or creatine kinase (CK) level \\> 3 times the upper limit of normal range as measured within the past 30 days and determined to be non-transient through repeat testing;\n10. Pregnancy, breastfeeding, or women of childbearing potential who are not using an effective method of contraception;\n11. Any contraindication, known allergy or intolerance to colchicine;\n12. Colchicine use within 30 days prior to randomization, or planned colchicine therapy for other indications;\n13. Current or planned use of any of cyclosporine, verapamil, HIV protease inhibitors, azole antifungals, or macrolide antibiotics;\n14. Existing or planned treatment with other anti-inflammatory or immunosuppressive drugs;\n15. History of malignancy (hematologic or solid-tumor);\n16. History of transplantation (hematopoietic stem cell or solid-organ);\n17. Significant radiation exposure (≥40 mSv) within the past 12 months;\n18. Known hypersensitivity to iodinated contrast media or uncontrolled active hyperthyroidism;\n19. Current enrollment in another clinical trial;\n20. A predicted life expectancy \\\u003C 1 year;\n21. Any other circumstances in which the investigator judges that the patient is not suitable to participate in the clinical trial.","ALL","40 Years","85 Years",{"count":20,"type":21},120,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","This study aims to investigate whether TET2-associated clonal hematopoiesis of indeterminate potential (TET2-CHIP) can serve as a biomarker to guide precision use of colchicine in a population of clinically stable post-ACS patients receiving standard of care (SoC) therapy. Specifically, we will evaluate whether TET2-CHIP status predicts a differential response to colchicine. As a pilot study, it also aims to provide detailed data supporting design of further trial, such as sample size calculating, endpoint optimizing, etc.",[27,28,29],"Colchicine","Coronary Atherosclerosis Management","Clonal Hematopoiesis of Indeterminate Potential","RECRUITING","2026-06-28",{"date":33,"type":34},"2026-06-30","ACTUAL",{"date":36,"type":34},"2026-06-08",{"date":38,"type":21},"2027-12-01",{"name":40,"class":41},"Shenyang Northern Hospital","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":16,"minAge":50,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":22,"phases":54,"briefSummary":56,"conditions":57,"keywords":59,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":4},"100627186","circumferential-pulmonary-venous-isolation-combined-with-bachmann-bundle-modification-versus-circumferential-pulmonary-venous-isolation-for-persistent-atrial-fibrillation-100627186","NCT07445360","Circumferential Pulmonary Venous Isolation Combined With Bachmann Bundle Modification Versus Circumferential Pulmonary Venous Isolation for Persistent Atrial Fibrillation","A Multicenter, Prospective, Randomized Controlled Study of Circumferential Pulmonary Venous Isolation Combined With Bachmann Bundle Modification Versus Circumferential Pulmonary Venous Isolation for Persistent Atrial Fibrillation","Inclusion Criteria:\n\n1. Subjects≥ 18 years old and ≤ 75 years old;\n2. the subject was diagnosed with persistent atrial fibrillation (duration of ≥6 months and ≤ 3 years);\n3. Able to understand the purpose of the trial, voluntarily participate in this study, the subject or his legal representative signed the informed consent form, and was willing to complete the follow-up according to the requirements of the protocol.\n\nExclusion Criteria:\n\n1. Previous atrial fibrillation catheter ablation therapy, left atrial appendage closure or atrial fibrillation surgery;\n2. atrial fibrillation secondary to electrolyte imbalances, thyroid disease or other reversible disease, or non-cardiac causes;\n3. Left atrial or left atrial appendage thrombus (confirmed by esophageal ultrasound or CT examination);\n4. Patients with pulmonary vein stenosis or pulmonary vein stents implanted;\n5. Have had atrial septal repair or atrial myxoma;\n6. Severe structural heart disease (such as moderate to severe mitral regurgitation, dilated cardiomyopathy, hypertrophic cardiomyopathy, severe heart valve disease);\n7. Cardiac ultrasound showed that the diameter of the left atrium was ≥50mm\n8. New York College of Cardiology (NYHA) cardiac function grades III and IV; LVEF\\\u003C40%；\n9. Those with cerebrovascular diseases (including stroke, transient ischemic attack) in the past 3 months;\n10. Those who have had cardiovascular events in the past 3 months (including acute myocardial infarction, coronary intervention or heart bypass);\n11. surgery, prosthetic valve replacement or repair, atrial or ventriculotomy;\n12. Those with acute or severe systemic infection;\n13. Combined with severe liver and kidney insufficiency (AST or ALT≥ 3 times the upper limit of normal; SCr\\>3.5mg\u002Fdl or Ccr\\\u003C30ml\u002Fmin);\n14. Those with obvious bleeding tendency and hematologic diseases, or contraindications to anticoagulation;\n15. Patients with malignant tumors and end-stage diseases with a life expectancy of \\\u003C 12 months; After chemotherapy or radiotherapy for malignant tumors;\n16. The subject is a female who is pregnant or lactating or cannot use contraception during the trial;\n17. The subject has participated in clinical trials of other drugs or devices during the same period;\n18. Abnormalities or diseases that, in the opinion of the investigator, should be excluded from the scope of enrollment in this study.","18 Years","75 Years",{"count":53,"type":21},320,[55],"NA","This study is a prospective, randomized controlled, single-blind, multicenter study design. To evaluate the safety and efficacy of traditional pulmonary vein isolation (PVI) alone and PVI combined with Bachmann bundle ablation on persistent atrial fibrillation.\n\nAccording to the treatment strategy, they were divided into two groups. Control group: circumferential PVI alone group (CPVI). Experimental group: CPVI combined with Bachmann bundle ablation group (CPVI-BBM).",[58],"Persistent Atrial Fibrillation",[60,61],"Circumferential pulmonary venous isolation","Bachmann bundle modification","NOT_YET_RECRUITING","2026-05-06",{"date":65,"type":34},"2026-05-11",{"date":67,"type":21},"2026-05-01",{"date":69,"type":21},"2028-12-31",{"name":40,"class":41},{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":75,"acronym":76,"eligibilityCriteria":77,"healthyVolunteers":11,"sex":16,"minAge":50,"maxAge":4,"enrollmentInfo":78,"targetDuration":4,"studyType":22,"phases":80,"briefSummary":81,"conditions":82,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":91,"leadSponsor":92,"locationsCount":4},"100622402","phase-4-bivalirudin-versus-heparin-during-pci-in-high-bleeding-risk-patients-with-acute-coronary-syndromes-100622402","NCT07383155","Bivalirudin Versus Heparin During PCI in High Bleeding Risk Patients With Acute Coronary Syndromes","BRIGHT-HBR","Inclusion Criteria:\n\n* Age ≥18 years\n* Clinical evidence of NSTE-ACS or recent stabilized STEMI (≥48 hours after symptom onset) undergoing PCI\n* The patient meets the ARC criteria for HBR (≥1 major criterion or ≥2 minor criteria)\n* The patient or legal representative has been fully informed and written informed consent has been obtained\n\nExclusion Criteria:\n\n* STEMI patients within 48 hours of symptom onset\n* CABG or PCI within the prior 6 months, including for the present clinical syndrome\n* Cardiogenic shock\n* Coronary artery disease unsuitable for revascularization or requiring CABG\n* Confirmed or suspected aortic dissection\n* Treatment with a glycoprotein IIb\u002FIIIa inhibitor within 2 hours prior to the PCI (use of intravenous heparin prior to or at the time of randomization is acceptable)\n* Allergy to UFH, bivalirudin, aspirin, clopidogrel, ticagrelor, or contrast agents that cannot be adequately pre-medicated, or any prior anaphylaxis to these agents\n* Any non-cardiac conditions with an expected life expectancy of ≤12 months\n* Patients deemed by the investigator to be clinically unsuitable for coronary angiography and PCI, or who are unlikely to be able to comply with the protocol requirements, including medication adherence and follow-up visits",{"count":79,"type":21},5270,[24],"Background. Randomized data on the optimal parenteral anticoagulant during percutaneous coronary intervention (PCI) in high bleeding risk (HBR) patients with acute coronary syndromes (ACS) are lacking.\n\nMethods. BRIGHT-HBR is an investigator-sponsored, open-label, randomized controlled trial comparing bivalirudin vs. unfractionated heparin (UFH) monotherapy in HBR patients with ACS undergoing PCI. A total of 5270 HBR patients with a non-ST-elevation acute coronary syndrome (NSTE-ACS) or recent stabilized ST-segment elevation myocardial infarction (STEMI, ≥48 hours after symptom onset) will be randomized 1:1 to bivalirudin or UFH at 70 sites in China. HBR is defined by the Academic Research Consortium (ARC)-HBR criteria. The primary composite endpoint is net adverse clinical events (NACE) at 30 days, the composite of all-cause death, myocardial infarction, stroke, urgent target-vessel revascularization, or BARC types 2, 3 or 5 bleeding, and the major secondary endpoint is BARC types 2, 3 or 5 bleeding. The study is powered to demonstrate that bivalirudin is superior to UFH monotherapy for NACE in ACS patients with HRB at 30 days after PCI.\n\nConclusions. The BRIGHT-HBR randomized trial aims to provide evidence on whether bivalirudin reduces the incidence of NACE and clinically relevant bleeding compared with UFH monotherapy in patients with ACS who are at HBR undergoing PCI.",[83,84,85,86],"Percutaneous Coronary Intervention","High Bleeding Risk","Acute Coronary Syndromes","Anticoagulant Therapy","2026-02-01",{"date":89,"type":34},"2026-02-03",{"date":87,"type":21},{"date":69,"type":21},{"name":40,"class":41},{"id":94,"slug":95,"hasResults":11,"nctId":96,"briefTitle":97,"officialTitle":98,"acronym":4,"eligibilityCriteria":99,"healthyVolunteers":11,"sex":16,"minAge":50,"maxAge":4,"enrollmentInfo":100,"targetDuration":4,"studyType":22,"phases":102,"briefSummary":103,"conditions":104,"keywords":108,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":42},"100621753","safety-and-efficacy-of-de-escalation-dual-antiplatelet-therapy-after-biofreedom-stenting-in-acs-patients-with-moderate-to-high-ischemic-and-high-bleeding-risk-100621753","NCT07374718","Safety and Efficacy of De-escalation Dual Antiplatelet Therapy After BioFreedom™ Stenting in ACS Patients With Moderate-to-high Ischemic and High Bleeding Risk","Optimization and Verification of Quality Control Indicators for Coronary Revascularization Based on Antiplatelet Therapy: Safety and Efficacy of De-escalation Dual Antiplatelet Therapy in Moderate-to-high Ischemic Risk and High Bleeding Risk ACS Patients After BioFreedom™ Drug-Coated Coronary Stenting","Inclusion Criteria:\n\n* Aged ≥ 18 years old\n* ACS patients with high bleeding risk (meeting the ARC-HBR criteria)\n* Moderate-to-high ischemic risk (OPT-CAD score ≥ 90)\n* Predicted by the investigator to be able to tolerate 12 months of DAPT\n* Voluntarily participate and sign the informed consent form, and be willing to receive the designated follow-up of this trial at specific time points\n* Coronary artery lesions are primary and in-situ coronary artery lesions\n* Target lesion diameter stenosis ≥ 70% or ≥ 50% (visual estimation) accompanied by evidence of myocardial ischemia\n\nExclusion Criteria:\n\n* Patients with known allergy or contraindication to P2Y12 inhibitors, aspirin, or contrast agents\n* Patients planning to undergo surgical intervention within 12 months\n* Left Ventricular Ejection Fraction (LVEF) \\\u003C 35%\n* Patients with contraindications to PCI\n* Patients with a history of substance abuse (alcohol, cocaine, heroin, etc.), or with an expected life expectancy of less than 1 year\n* Subjects with poor compliance or judged by the investigator to be unsuitable for participating in the study\n* Female patients who are planning to be pregnant or are pregnant\u002Flactating, and male patients planning to impregnate\n* Chronic total occlusion lesions\n* Lesions involving the left main coronary artery\n* Severe calcified and tortuous lesions",{"count":101,"type":21},468,[55],"Patients with acute coronary syndrome (ACS) who have both high ischemic risk and high bleeding risk represent a challenging population following percutaneous coronary intervention (PCI), as prolonged dual antiplatelet therapy (DAPT) may reduce ischemic events but increases bleeding complications.This prospective, multicenter, randomized controlled study evaluates the safety and effectiveness of an optimized PCI and antiplatelet therapy strategy in ACS patients with moderate-to-high ischemic risk and high bleeding risk. Eligible patients will be randomized in a 1:1 ratio to either an experimental strategy consisting of intravascular ultrasound-guided implantation of a polymer-free drug-coated stent followed by one month of DAPT and subsequent single antiplatelet therapy, or a control strategy consisting of angiography-guided implantation of contemporary drug-eluting stents followed by standard 12-month DAPT.The primary hypothesis is that the experimental strategy will reduce the incidence of net adverse clinical events, defined as a composite of ischemic and bleeding outcomes, compared with conventional PCI and prolonged DAPT. Participants will be followed for 12 months after the index procedure.",[105,106,107],"Acute Coronary Syndrome (ACS)","High Bleeding Risk(HBR)","Coronary Artery Disease (CAD)",[109,105,110,111,112,113,114,115,116,117],"Dual Antiplatelet Therapy (DAPT)","High Bleeding Risk (HBR)","Percutaneous Coronary Intervention (PCI)","Quality Control Indicators","Coronary Revascularization","Real-World Research","Bleeding Events","Ischemic Events","Post-PCI Prognosis","2026-01-20",{"date":120,"type":34},"2026-01-29",{"date":122,"type":21},"2026-03-01",{"date":124,"type":21},"2029-06-30",{"name":40,"class":41},{"id":127,"slug":128,"hasResults":11,"nctId":129,"briefTitle":130,"officialTitle":131,"acronym":4,"eligibilityCriteria":132,"healthyVolunteers":11,"sex":16,"minAge":50,"maxAge":4,"enrollmentInfo":133,"targetDuration":135,"studyType":136,"phases":4,"briefSummary":137,"conditions":138,"keywords":139,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":144,"startDateStruct":146,"completionDateStruct":148,"leadSponsor":149,"locationsCount":42},"100620223","optimization-and-validation-of-quality-control-indicators-for-coronary-revascularization-based-on-antiplatelet-therapy-100620223","NCT07354828","Optimization and Validation of Quality Control Indicators for Coronary Revascularization Based on Antiplatelet Therapy","Optimization and Validation of Quality Control Indicators for Coronary Revascularization Based on Antiplatelet Therapy: Establishment of a Quality Control Standard System for Coronary Revascularization in Coronary Heart Disease Based on Dual Antiplatelet Therapy (DAPT)","Inclusion Criteria:\n\n* Aged ≥ 18 years\n* Clinically diagnosed with ACS and received implantation of at least one drug-eluting stent (DES)\n* Meets 1 major criterion or 2 minor criteria of the ARC-HBR high-bleeding-risk definition\n* Able to complete the OPT-CAD score calculation\n* Judged by the investigator to tolerate DAPT for at least 12 months\n* Signed the informed consent form\n\nExclusion Criteria:\n\n* Allergy to study medications such as aspirin, clopidogrel, or ticagrelor\n* Occurrence of major ischemic or bleeding events during the current hospitalization\n* Presence of other severe diseases with a life expectancy of less than one year\n* Pregnancy, or women of childbearing potential who plan to become pregnant within one year\n* Current participation in another clinical study and still within its observation period.",{"count":134,"type":21},3500,"12 Months","OBSERVATIONAL","Study Purpose Coronary heart disease (CAD) is a leading global cause of death, with Acute Coronary Syndrome (ACS) as its acute and life-threatening subtype. Percutaneous Coronary Intervention (PCI) plus stent implantation is the first-line treatment for ACS, and post-PCI Dual Antiplatelet Therapy (DAPT, aspirin + P2Y₁₂ inhibitor) is core for thrombosis prevention but increases bleeding risk. Approximately 40% of ACS patients are classified as High Bleeding Risk (HBR). China lacks a unified DAPT quality control system, and the predictive value of the OPT-CAD ischemic risk score for this population remains unvalidated. This study aims to: 1) Evaluate the feasibility and influencing factors of the DAPT quality control system in HBR ACS patients post-PCI; 2) Verify the accuracy of the OPT-CAD score in predicting ischemic risk, providing evidence for personalized treatment.\n\nEligibility Criteria Inclusion Criteria Aged ≥18 years; Diagnosed with ACS and implanted with at least one drug-eluting stent (DES) during PCI; Meets ARC-HBR (Academic Research Consortium for High Bleeding Risk) HBR definition (1 major criterion or 2 minor criteria); Able to complete OPT-CAD scoring; Tolerates 12-month DAPT (physician assessment); Signs informed consent. Exclusion Criteria Allergy to aspirin, clopidogrel, ticagrelor, or other study-related antiplatelet drugs; Severe ischemia or major bleeding during current hospitalization; Terminal illness with life expectancy \\\u003C1 year; Pregnant or planning pregnancy within 1 year; Enrolled in other ongoing clinical studies. Study Process\n\nThis is a multi-center prospective cohort study (we will follow eligible patients over 12 months to collect real-world data without changing their standard care) recruiting 3,500 participants nationwide. Post-enrollment:\n\nReceive 6-12 months of standard DAPT (regimen determined by your physician); Follow-ups at 1 month (±7 days), 3 months (±14 days), 6 months (±30 days), and 12 months (±30 days) post-PCI (via phone or outpatient visit) to collect medication adherence, bleeding\u002Fischemic events, and clinical outcomes; Confidential data collection via a secure Electronic Data Capture (EDC) system. Study Endpoints Primary Endpoints Feasibility of the DAPT quality control system, inter-hospital differences in DAPT use, 6-12 month DAPT completion rate, and impact of DAPT interruption on patient outcomes; Accuracy of the OPT-CAD score in predicting ischemic risk for HBR patients. Secondary Endpoints 12-month bleeding event rates (BARC 1-5 types, including minor bleeding like puncture site bleeding and major bleeding like intracranial hemorrhage); 12-month ischemic event rates (including target lesion failure-cardiac death, target vessel-related myocardial infarction, or target lesion revascularization-all-cause death, ischemic stroke, definite stent thrombosis, etc.); DAPT interruption rate, P2Y₁₂ inhibitor discontinuation rate (≥1 week), and aspirin discontinuation rate (≥1 week).\n\nKey Information for Participants Voluntary participation: You may withdraw anytime without penalty or loss of medical benefits; Confidential data protection: Personal information will be anonymized with a unique study ID; Free study-related assessments and follow-ups; Prompt medical care will be provided for any adverse events. For inquiries, contact the study team at the participating hospital.",[105,110,107],[109,105,110,111,140,112,113,141,114,115,116,142,117],"OPT-CAD Score","Prospective Cohort Study","Medication Adherence","2026-01-12",{"date":145,"type":34},"2026-01-21",{"date":147,"type":21},"2025-12-30",{"date":124,"type":21},{"name":40,"class":41},{"id":151,"slug":152,"hasResults":11,"nctId":153,"briefTitle":154,"officialTitle":155,"acronym":156,"eligibilityCriteria":157,"healthyVolunteers":11,"sex":16,"minAge":50,"maxAge":4,"enrollmentInfo":158,"targetDuration":4,"studyType":22,"phases":160,"briefSummary":161,"conditions":162,"keywords":165,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":171,"startDateStruct":172,"completionDateStruct":174,"leadSponsor":176,"locationsCount":42},"100619978","phase-4-ccta-evaluation-of-sglt2i-related-pericoronary-fat-changes-in-non-diabetic-acs-patients-without-hf-100619978","NCT07351643","CCTA Evaluation of SGLT2i-related Pericoronary Fat Changes in Non-diabetic ACS Patients Without HF","Assessment of the Effects of SGLT2 Inhibitors on Pericoronary Fat in Non-diabetic ACS Patients Without Heart Failure Using CCTA","DAPA-PCAT","Inclusion Criteria:\n\n1. Age ≥18 years\n2. Diagnosis of acute coronary syndrome (including ST-elevation myocardial infarction, non-ST-elevation myocardial infarction, or unstable angina)\n3. Undergoing percutaneous coronary intervention (PCI)\n4. Presence of multivessel coronary artery disease with at least one non-culprit vessel not undergoing revascularization (for CCTA follow-up assessment)\n5. Willing and able to provide written informed consent\n\nExclusion Criteria:\n\n1. Prior or current diagnosis of diabetes mellitus\n2. Prior or current diagnosis of chronic heart failure\n3. Treatment with any SGLT2 inhibitor within 4 weeks prior to enrollment\n4. Severe hepatic impairment\n5. History of recurrent urogenital infections\n6. Known allergy or intolerance to SGLT2 inhibitors\n7. Pregnancy or breastfeeding\n8. Systolic blood pressure \\\u003C90 mmHg and\u002For diastolic blood pressure \\\u003C60 mmHg\n9. Severe chronic kidney disease (eGFR \\\u003C30 mL\u002Fmin\u002F1.73 m²)\n10. Current participation in another interventional clinical trial\n11. Any other condition that, in the opinion of the investigator, would make the participant unsuitable for enrollment",{"count":159,"type":21},110,[24],"The goal of this clinical trial is to learn if dapagliflozin, a sodium-glucose cotransporter 2 inhibitor (SGLT2i), can reduce coronary artery inflammation in people with acute coronary syndrome (ACS) who do not have diabetes or heart failure.\n\nCoronary inflammation will be measured using the fat attenuation index (FAI), a marker derived from coronary CT angiography (CCTA) that quantifies inflammation in the fat tissue surrounding heart arteries.\n\nThe main questions it aims to answer are:\n\n* Does dapagliflozin lower coronary artery inflammation as measured by FAI?\n* Does dapagliflozin slow the progression of coronary plaques?\n\nResearchers will compare participants who take dapagliflozin 10 mg daily plus standard therapy to those who receive standard therapy alone for 6 months.\n\nParticipants will:\n\n* Undergo percutaneous coronary intervention (PCI) for ACS\n* Have a baseline CCTA scan at 1 month after PCI, at which point they will be randomly assigned to receive dapagliflozin or standard care alone\n* Have a follow-up CCTA scan at 6 months after randomization\n* Have blood tests at the time of PCI, at randomization, and at 6 months after randomization\n* Receive follow-up phone calls at 3 and 6 months after randomization",[163,164],"ACS (Acute Coronary Syndrome)","SGLT2 Inhibitors",[166,167,168,169,170],"Fat attenuation index","SGLT2 inhibitors","Pericoronary adipose tissue","Residual inflammatory risk","Coronary CT angiography",{"date":118,"type":34},{"date":173,"type":21},"2026-02-25",{"date":175,"type":21},"2026-12-30",{"name":40,"class":41},{"id":178,"slug":179,"hasResults":11,"nctId":180,"briefTitle":181,"officialTitle":182,"acronym":183,"eligibilityCriteria":184,"healthyVolunteers":11,"sex":16,"minAge":50,"maxAge":185,"enrollmentInfo":186,"targetDuration":4,"studyType":22,"phases":188,"briefSummary":189,"conditions":190,"keywords":192,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":197,"lastUpdatePostDateStruct":198,"startDateStruct":200,"completionDateStruct":202,"leadSponsor":204,"locationsCount":42},"100605282","early-thrombolysis-guided-by-ai-assisted-app-in-patients-with-stemi-100605282","NCT07160491","Early Thrombolysis Guided by AI-Assisted App in Patients With STEMI","Early Pre-hospital Thrombolysis Guided by Artificial Intelligence Assisted Mobile Application in Patients With ST-elevation Myocardial Infarction: A Multi-center Cluster Randomized Controlled Trial","EARLY-OPEN","Inclusion Criteria:\n\n* (the following inclusion conditions shall be met at the same time):\n\n  1. age: ≥ 18 years and ≤ 80 years;\n  2. Chest pain lasted for more than 30 min, and the onset time of chest pain was ≤ 12 hours;\n  3. ECG: ST segment elevation after J-point in 2 or more adjacent leads: limb leads ≥ 0.1 mv or chest leads ≥ 0.2 mv;\n  4. it is expected that \"guide wire passing through the lesion\" could not be achieved within 120 min after the diagnosis of STEMI;\n  5. Signed informed consent .\n\nExclusion Criteria:\n\n* (1) Cardiac rupture; (2) Complete left bundle branch block (LBBB) or ventricular pacing; (3) There are contraindications to thrombolysis; (4) Have serious comorbidities; (5) Have complex heart disease; (6) There are situations that are not suitable for clinical trials.","80 Years",{"count":187,"type":21},3356,[55],"The aim of the study is to elucidate whether guiding by a novel artificial intelligence assisted mobile application can improve the clinical outcomes of patients in whom \"guide wire passing through the lesion\" could not be achieved within 120 min after diagnosis of STEMI, compared to conventional treatment strategies. With concerns of the inadequate use of thrombolysis in patients with STEMI in China, this study applies a new artificial intelligence assisted mobile application to guide the process of thrombolysis combined with PCI treatment, in order to accomplish the rapid coordination and cooperation of the whole medical network during re-perfusion treatment in different regions and different medical institutions in China, increases the proportion of early thrombolysis in pre-hospital setting, shortens the time from STEMI onset to reperfusion, and provides a reliable, effective and replicable new strategy for promoting and optimizing early reperfusion.",[191],"STEMI - ST Elevation Myocardial Infarction",[193,194,195,196],"Thrombolysis","appliaction","myocardial infarction","cluster randomized trial","2025-09-14",{"date":199,"type":34},"2025-09-18",{"date":201,"type":34},"2025-09-08",{"date":203,"type":21},"2029-07-31",{"name":40,"class":41},{"id":206,"slug":207,"hasResults":11,"nctId":208,"briefTitle":209,"officialTitle":210,"acronym":211,"eligibilityCriteria":212,"healthyVolunteers":11,"sex":16,"minAge":50,"maxAge":4,"enrollmentInfo":213,"targetDuration":215,"studyType":136,"phases":4,"briefSummary":216,"conditions":217,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":219,"lastUpdatePostDateStruct":220,"startDateStruct":222,"completionDateStruct":224,"leadSponsor":226,"locationsCount":42},"100532748","clinical-outcomes-of-patients-with-coronary-artery-disease-100532748","NCT06216847","Clinical Outcomes of Patients With Coronary Artery Disease","Clinical Outcomes of Patients With Coronary Artery Disease Cohort Study","COCAD","Inclusion Criteria:\n\n* Age ≥ 18 years old\n* Hospitalization due to either confirmed or suspected CHD combined with one of the following features: previous PCI or CABG; previous myocardial infarction; previous coronary angiography revealing ≥ 50% stenosis in major coronary vessels; presentation with chest pain and pre-test probability of CHD \\> 65%; laboratory tests revealing objective evidence of myocardial ischemia; coronary CT angiography (CTA) showed ≥ 30% stenosis in major coronary vessels\n* Subjects undergoing at least one coronary imaging and one functional examination. Imaging examinations include coronary CTA, intravascular ultrasound (IVUS), or optical coherence tomography (OCT). Functional examination include fraction flow reservation (FFR), CT-FFR or quantitative flow ratio (QFR).\n* Written informed consent provided.\n\nExclusion Criteria:\n\n* History of mental illness, drug or alcohol abuse, or being unable to cooperate with follow-up visits for any reason;\n* Life expectancy \\\u003C1 year\n* Pregnant or plan to be pregnant within 1 year\n* Subjects participating in any other clinical trial\n* Other conditions deemed unsuitable for inclusion by the investigator",{"count":214,"type":21},10000,"5 Years","Coronary heart disease (CHD) stands as a foremost contributor to global mortality, characterized by complex pathogenesis that renders conventional \"one-size-fits-all\" preventive strategies inefficient. Therefore, the investigators designed a prospective, multi-center cohort study among patients hospitalized due to either confirmed or suspected CHD, which aimed to establish a holographic data set for the diagnosis and treatment of CHD and explore the impact of critical therapeutic strategies in the real world on the clinical outcomes of CHD patients, providing evidence to optimize the management pathway.",[218],"Coronary Heart Disease (CHD)","2025-09-03",{"date":221,"type":34},"2025-09-10",{"date":223,"type":34},"2024-02-21",{"date":225,"type":21},"2030-10-31",{"name":40,"class":41},{"id":228,"slug":229,"hasResults":11,"nctId":230,"briefTitle":231,"officialTitle":232,"acronym":233,"eligibilityCriteria":234,"healthyVolunteers":11,"sex":16,"minAge":50,"maxAge":185,"enrollmentInfo":235,"targetDuration":4,"studyType":22,"phases":237,"briefSummary":238,"conditions":239,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":219,"lastUpdatePostDateStruct":241,"startDateStruct":242,"completionDateStruct":244,"leadSponsor":246,"locationsCount":42},"100532746","opt-cad-score-guided-dual-antiplatelet-de-escalation-time-100532746","NCT06216821","OPT-CAD Score GUIded Dual ANtiplatelet De-esCalation Time","OPT-CAD Score Guided Dual Antiplatelet De-escalation Time in Patients With Acute Coronary Syndrome Undergoing Undergoing Percutaneous Coronary Intervention: a Register-based Randomized Controlled Study","OPT-GUIDNACE","Inclusion Criteria:\n\n1. Adult patients with ages of 18-80 years;\n2. Patients with clinically diagnosed ACS who have undergone at least one DES implantation;\n3. Individuals capable of completing the OPT-CAD scoring calculation;\n4. Researchers assessing that participants can tolerate at least a 12-month duration of DAPT therapy;\n5. Written informed consent provided.\n\nExclusion Criteria:\n\n1. Left main coronary artery lesion PCI;\n2. Allergy to study drugs such as aspirin, clopidogrel, or ticagrelor;\n3. Meeting 1 major or 2 minor criteria for high bleeding risk according to the ARC-HBR criteria;\n4. Anticipated need for revascularization or surgical intervention within 12 months;\n5. Severe ischemia or hemorrhage events during the current hospitalization;\n6. Life expectancy of other serious diseases is less than 1 year;\n7. Pregnant or women of childbearing age who intend to conceive within 1 year;\n8. Participation in other clinical trials while still under observation;\n9. Researchers considering ineligibility for enrollment.",{"count":236,"type":21},3490,[55],"Monotherapy with a P2Y12 inhibitor after a minimum period of DAPT following percutaneous coronary intervention (PCI) is an emerging de-escalation antiplatelet strategy in recent years. However, the optimal timing for de-escalating DAPT in ACS patients undergoing PCI remains debated. The OPT-CAD score is a risk stratification tool derived from Chinese patients which has been demonstrated superior predictive capabilities for ischemic events and all-cause mortality than the GRACE score. Therefore, we hypothesize that the OPT-CAD score can be used to guide the timing of the DAPT de-escalation strategy to monotherapy with P2Y12 inhibitors for ACS patients, that is, low-risk patients could be de-escalated after 1 month, while high-risk patients could be de-escalated after 3 months, so as to achieve individualized antithrombotic therapy and maximize patient benefit.",[240],"Acute Coronary Syndrome",{"date":221,"type":34},{"date":243,"type":34},"2024-07-02",{"date":245,"type":21},"2027-12-31",{"name":40,"class":41},{"id":248,"slug":249,"hasResults":11,"nctId":250,"briefTitle":251,"officialTitle":252,"acronym":4,"eligibilityCriteria":253,"healthyVolunteers":254,"sex":16,"minAge":50,"maxAge":51,"enrollmentInfo":255,"targetDuration":4,"studyType":22,"phases":257,"briefSummary":259,"conditions":260,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":266,"lastUpdatePostDateStruct":267,"startDateStruct":269,"completionDateStruct":270,"leadSponsor":272,"locationsCount":42},"100542142","early-phase-1-oct-or-angiography-guided-de-escalation-of-dapt-100542142","NCT06339021","OCT or Angiography Guided De-escalation of DAPT","Evaluation of Neointimal Coverage After Guiding De-escalation of Antiplatelet Treatment in Patients With ST-elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention by Optical Coherence Tomography or Angiography of STEMI Patients","Inclusion Criteria:\n\n1. 18 \\~ 85 years old adult patients;\n2. Patients diagnosed with STEMI and undergoing PCI.\n3. Patients able and willing to give written informed consent and to comply with the requirements of this study protocol.\n\nExclusion Criteria:\n\n1. Prior history of intracranial hemorrhage or ischemic stroke during the past 6 months；\n2. Allergy to aspirin or clopidogrel or ticagrelor;\n3. Occurrence of major adverse cardiovascular event (MACE) within 30 days after undergoing PCI;\n4. Platelet count \\\u003C 50 × 109\u002FL;\n5. Major bleeding during the past 12 months;\n6. Any form of oral, long-term anticoagulation therapy;\n7. Pregnancy or lactation;\n8. Suspected aortic dissection;\n9. Coronary CT-negative patients;\n10. Life expectancy \\\u003C1 year;\n11. Uncontrolled hypertension, systolic blood pressure (SBP) ≥180 mmHg, and\u002For diastolic blood pressure (DBP) ≥110 mmHg;\n12. Comorbid conditions included the presence of any of the following: cardiogenic shock, chronic congestive heart failure with NYHA classes III or IV, left ventricular ejection fraction (LVEF) \\\u003C 35% at transthoracic echocardiography, hypotension with SBP \\\u003C 90mmHg and\u002For DBP \\\u003C 60mmHg, severe arrhythmia (including high-degree AV block, sick sinus syndrome, sustained ventricular tachycardia), severe pulmonary insufficiency, pulmonary embolism, hepatic insufficiency due to non-cardiac causes (ALT or AST more than three times the upper limit of the institution's normal reference ranges), cirrhosis, severe renal failure (eGFR \\\u003C 30ml\u002Fmin\u002F1.73m2);\n13. Surgery plan within 30 days;\n14. Psychiatric abnormalities or alcohol dependence;\n15. Patients who are participating in other clinical trials;\n16. Unable to tolerate 1 month of DAPT;\n17. Angiographic triple vessel disease coronary disease;\n18. Other situations judged by the investigators not to be suitable for the clinical trial.",true,{"count":256,"type":21},80,[258],"EARLY_PHASE1","Optical coherence tomography (OCT) offers a high-resolution intravascular imaging modality to accurately assess vessel and lumen geometry and identify the hallmark of a culprit lesion including plaque disruption and thrombus. In addition, the incorporation of the MLD MAX algorithm into daily practice guides an efficient and easily-memorable workflow for optimized OCT-guided percutaneous coronary intervention (PCI) with drug-eluting stents (DES). Regarding the antithrombotic therapy after revascularization, the 2023 ESC guidelines recommend the P2Y12 receptor inhibitor de-escalation (i.e. switching from ticagrelor to clopidogrel) in ACS patients may be considered as an alternative strategy to the default treatment regimen in order to reduce the risk of bleeding events.\n\nBased on the above conclusions, we designed a single-center, prospective, randomized controlled, exploratory study trial to evaluate whether the utility of OCT for guiding PCI with DES followed by antiplatelet de-escalation therapy could further reduce the stent-induced intimal hyperplasia of STEMI patients after stent implantation.",[261,262,263,264,265],"Optical Coherence Tomography","Dual Antiplatelet Therapy","Antiplatelet De-escalation","Neointimal Coverage","ST Elevation Myocardial Infarction","2024-03-24",{"date":268,"type":34},"2024-04-01",{"date":268,"type":21},{"date":271,"type":21},"2026-12-01",{"name":40,"class":41},""]